Strong capex payoff masks pricing dependency; long-term visible but Q2 reset incoming

Delivered 37.6% to ₹5,366 Cr — essentially matched (0.4% variance)

EBITDA ₹920 Cr ÷ ₹5,366 Cr = 17.1% — matches claim exactly

Q1 alone is ₹5,366 Cr (37.6% of FY26 run-rate). Full year 35% implies ~₹21,150 Cr. Mathematically tight—Q2 must see significant continuation or margin compression.

Volume 173,471 MT (+1.7%), BOPP prices +25%, BOPET +30-35%. Verified in call. Growth entirely price/mix driven, not volume.

Tacit admission Q1 is non-repeatable. Q1 PAT ₹423 Cr already 70% of likely full-year guidance (₹600 Cr base + 35% = ₹810 Cr), leaving only ₹387 Cr for 3 quarters.

12 billion pack capacity, if operating Oct 1 → 6 months = 6B, 30% = 1.8-2B packs. Claims 2B from Egypt FY27. Consistent and credible if commission Oct 1.

Prior FY26 call: vague 'improved performance, better utilization, new capacities.' Now: explicit 35% growth (both revenue and EBITDA), 14%+ margin, 10% CAGR to FY29.

Spoke about FY29 as target multiple times; doubled volume, Egypt 100% utilization, 3 major capex live. Raises long-term credibility vs prior single-quarter focus.

Q1 exceptional → Q2 normalization; volume growth stuck at 1.7%; domestic segment profitability weak (40% revenue growth, 15% of PAT); hedging on geopolitical (West Asia, Bab-el-Mandeb).

Egypt USD 100M+ committed; Dharwad, Mexico, Noida mostly capitalized. Remaining USD 80-100M for FY27. Less cash drag but payoff dependent on ramp.

Prices up 30% vs West Asia war start; BOPP +25%, BOPET +30-35% from Feb '26 levels; raw material rising less; spreads stable, pricing structural.

Yes, absolutely sustainable; growth is result of 2-3 years capex ramping; capex takes 3 years to reach 100% potential; momentum strong, better results ahead.

Hard to give guidance in geopolitical uncertainty; expecting 35% growth in top line and EBITDA in FY27 compared to FY26.

Benchmark year-on-year not quarter-on-quarter; 35% growth on FY26 base is target; 30% plus growth expected; don't do quarter-level arithmetic.

Egypt 12B packs, USD 100M+ done, USD 15M remaining; Dharwad USD 50M+ FY27-28; Mexico USD 54M done; Noida USD 32M done; 75% of FY27 capex cycle complete.

30% is annualized; if operating Oct 1, 6 months = 6B capacity, 30% = ~2B packs; full utilization Year 3; impact visible Q3-Q4.

Prices quite stable; no major correction expected while West Asia crisis persists; raw material + finished pricing maintain margin; confident holding margins all year.

Don't carry inventory; prices passed to customers; pricing structural due to integrated supply chain, customers value reliability and pay premium; not one-off.

60-65% business overseas; overseas price 2.5x India; India competitive pricing, careful positioning; India FMCG growing 5-8%, packaging will follow; as India catches up margins improve.

Should double volume in 3 years; WPP, Egypt, Noida recycling fully utilized by FY29 will drive much bigger volume forward.

Everything not mathematics in business; look full year perspective; expect 14% plus margin; if geopolitical calm, better than 14%; don't calculate mathematically.

Debt-EBITDA was 4.5x FY26, now 3.5x, targeting <3x by FY28; leverage conscious and under control; paying all loans/interest on time.

Based on capex payoff and sustained pricing; dependent on geopolitical stability and volume recovery. Q1 ₹5,366 Cr is 37.6% of likely annual run-rate; Q2 flagged for normalization.

Management hedged: 'if geopolitical calm, can do better.' Implies 14% is floor, not target. Aseptic dumping and domestic pricing pressure are headwinds.

Contingent on capex ramps (Egypt, Dharwad, Mexico, Noida) reaching target utilization. No specific margin committed beyond 'growth continues.'

Specific capex allocation: Egypt USD 15M, Dharwad USD 50M+ (FY27-28), contingent spending. 60-70% of new capex to value-added products (Aseptic, WPP, recycling).

37.6% revenue growth on 1.7% volume = 94% from pricing (BOPP +25%, BOPET +30-35% vs Feb '26). If West Asia crisis ends or margins compress, guidance at risk. Management claims 'structural pricing power' but refused volume/price decomposition.

Total volume 173,471 MT (+1.7% YoY); Packaging Films +4.9%, but Packaging -8.4%. Packaging Films growth offset by Aseptic Packaging collapse (-8.4%) due to Indonesian import dumping. Volume recovery dependent on Aseptic market stabilization and India FMCG growth (5-8% expected but not guaranteed).

Egypt Aseptic targeting H1 FY27 but trials ongoing; ramp profile (30% Y1, 60-70% Y2, 100% Y3) dependent on technical execution and customer approvals. Dharwad BOPP and Mexico WPP already commissioned but ramp trajectory unproven. Failure to hit utilization targets would impact full FY27-29 growth thesis.

Domestic segment: +40% revenue growth but only 15% of consolidated PAT. Overseas price 2.5x India; domestic pricing competitive. Aseptic import dumping (Indonesia) cited as headwind. Management acknowledged gap but no turnaround timeline; expects India FMCG growth to lift with middleclass income expansion (₹20L → ₹30L).

West Asia crisis (Bab-el-Mandeb, Red Sea) cited as ongoing risk; US trade policy shifts affecting Americas sourcing; India-Indonesia treaty enabling duty-free aseptic imports. Management has de-risked by establishing 75% turnover 'near customer' policy (Egypt for MEA, Mexico for Americas, Europe for Europe, India for India). But India export-dependent facilities (if any) exposed.

Management flagged Q2 'normalization from exceptionally strong Q1 realization.' Q1 PAT ₹423 Cr already 70% of implied full-year guidance (₹600 Cr + 35% = ₹810 Cr). If Q2-Q4 average ₹129 Cr/quarter, guidance achieved but perceived as miss vs Q1 momentum.